Non-coding RNAs: Important Participants in Cardiac Fibrosis

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Aug 15

PMID 35966549

Authors

Yiheng Dong

Naling Peng

Lini Dong

Shengyu Tan

Xiangyu Zhang

Affiliations

Soon will be listed here.

Abstract

Cardiac remodeling is a pathophysiological process activated by diverse cardiac stress, which impairs cardiac function and leads to adverse clinical outcome. This remodeling partly attributes to cardiac fibrosis, which is a result of differentiation of cardiac fibroblasts to myofibroblasts and the production of excessive extracellular matrix within the myocardium. Non-coding RNAs mainly include microRNAs and long non-coding RNAs. These non-coding RNAs have been proved to have a profound impact on biological behaviors of various cardiac cell types and play a pivotal role in the development of cardiac fibrosis. This review aims to summarize the role of microRNAs and long non-coding RNAs in cardiac fibrosis associated with pressure overload, ischemia, diabetes mellitus, aging, atrial fibrillation and heart transplantation, meanwhile shed light on the diagnostic and therapeutic potential of non-coding RNAs for cardiac fibrosis.

Citing Articles

Emerging roles of non-coding RNAs in fibroblast to myofibroblast transition and fibrotic diseases.

Xing X, Rodeo S Front Pharmacol. 2024; 15:1423045.

PMID: 39114349 PMC: 11303237. DOI: 10.3389/fphar.2024.1423045.

Exosomal miRNA-21-5p and miRNA-21-3p as key biomarkers of myocardial infarction.

Sahebi R, Gandomi F, Shojaei M, Farrokhi E Health Sci Rep. 2024; 7(7):e2228.

PMID: 38983683 PMC: 11232052. DOI: 10.1002/hsr2.2228.

Analyses of lncRNA and mRNA profiles in recurrent atrial fibrillation after catheter ablation.

Tang H, Lu K, Wang Y, Shi Y, Ma W, Chen X Eur J Med Res. 2024; 29(1):244.

PMID: 38643140 PMC: 11031869. DOI: 10.1186/s40001-024-01799-3.

Noncoding RNAs regulating ferroptosis in cardiovascular diseases: novel roles and therapeutic strategies.

Wu C, Bao S, Sun H, Chen X, Yang L, Li R Mol Cell Biochem. 2023; 479(11):2827-2841.

PMID: 38064139 PMC: 11473578. DOI: 10.1007/s11010-023-04895-w.

Stem cell- derived extracellular vesicles as new tools in regenerative medicine - Immunomodulatory role and future perspectives.

Karnas E, Dudek P, Zuba-Surma E Front Immunol. 2023; 14:1120175.

PMID: 36761725 PMC: 9902918. DOI: 10.3389/fimmu.2023.1120175.

References

Song Y, Zhang C, Zhang J, Jiao Z, Dong N, Wang G . Localized injection of miRNA-21-enriched extracellular vesicles effectively restores cardiac function after myocardial infarction. Theranostics. 2019; 9(8):2346-2360. PMC: 6531307. DOI: 10.7150/thno.29945. View

Besler C, Urban D, Watzka S, Lang D, Rommel K, Kandolf R . Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J Heart Fail. 2016; 18(12):1442-1451. DOI: 10.1002/ejhf.579. View

Wang X, Wang H, Li Y, Zhang C, Zhou C, Wang L . MicroRNA Let-7i negatively regulates cardiac inflammation and fibrosis. Hypertension. 2015; 66(4):776-85. DOI: 10.1161/HYPERTENSIONAHA.115.05548. View

Li J, Rohailla S, Gelber N, Rutka J, Sabah N, Gladstone R . MicroRNA-144 is a circulating effector of remote ischemic preconditioning. Basic Res Cardiol. 2014; 109(5):423. DOI: 10.1007/s00395-014-0423-z. View

Li C, Li J, Xue K, Zhang J, Wang C, Zhang Q . MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction. J Mol Cell Cardiol. 2019; 129:281-292. DOI: 10.1016/j.yjmcc.2019.03.005. View

Lyu G, Guan Y, Zhang C, Zong L, Sun L, Huang X . TGF-β signaling alters H4K20me3 status via miR-29 and contributes to cellular senescence and cardiac aging. Nat Commun. 2018; 9(1):2560. PMC: 6028646. DOI: 10.1038/s41467-018-04994-z. View

Seo H, Lee S, Lee C, Lee J, Shin S, Song B . Multipoint targeting of TGF-β/Wnt transactivation circuit with microRNA 384-5p for cardiac fibrosis. Cell Death Differ. 2018; 26(6):1107-1123. PMC: 6748152. DOI: 10.1038/s41418-018-0187-3. View

Han P, Li W, Lin C, Yang J, Shang C, Nuernberg S . A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014; 514(7520):102-106. PMC: 4184960. DOI: 10.1038/nature13596. View

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-4. DOI: 10.1038/nature07511. View

10.

Hinkel R, Ramanujam D, Kaczmarek V, Howe A, Klett K, Beck C . AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury. J Am Coll Cardiol. 2020; 75(15):1788-1800. DOI: 10.1016/j.jacc.2020.02.041. View

11.

Schimmel K, Jung M, Foinquinos A, San Jose G, Beaumont J, Bock K . Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation. 2020; 141(9):751-767. PMC: 7050799. DOI: 10.1161/CIRCULATIONAHA.119.042559. View

12.

Chiasson V, Takano A, Guleria R, Gupta S . Deficiency of MicroRNA miR-1954 Promotes Cardiac Remodeling and Fibrosis. J Am Heart Assoc. 2019; 8(21):e012880. PMC: 6898847. DOI: 10.1161/JAHA.119.012880. View

13.

Omura J, Habbout K, Shimauchi T, Wu W, Breuils-Bonnet S, Tremblay E . Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation. 2020; 142(15):1464-1484. DOI: 10.1161/CIRCULATIONAHA.120.047626. View

14.

Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo M, Siniscalchi M . Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013; 15(11):1277-88. DOI: 10.1093/eurjhf/hft088. View

15.

Yu Y, Zhang Y, Ding Y, Bi X, Yuan J, Zhou H . MicroRNA-99b-3p promotes angiotensin II-induced cardiac fibrosis in mice by targeting GSK-3β. Acta Pharmacol Sin. 2020; 42(5):715-725. PMC: 8115164. DOI: 10.1038/s41401-020-0498-z. View

16.

Danielson K, Shah R, Yeri A, Liu X, Camacho Garcia F, Silverman M . Plasma Circulating Extracellular RNAs in Left Ventricular Remodeling Post-Myocardial Infarction. EBioMedicine. 2018; 32:172-181. PMC: 6020713. DOI: 10.1016/j.ebiom.2018.05.013. View

17.

Jeong D, Yoo J, Lee P, Kepreotis S, Lee A, Wahlquist C . miR-25 Tough Decoy Enhances Cardiac Function in Heart Failure. Mol Ther. 2017; 26(3):718-729. PMC: 5910658. DOI: 10.1016/j.ymthe.2017.11.014. View

18.

Zhang W, Wang Q, Feng Y, Chen X, Yang L, Xu M . MicroRNA-26a Protects the Heart Against Hypertension-Induced Myocardial Fibrosis. J Am Heart Assoc. 2020; 9(18):e017970. PMC: 7726969. DOI: 10.1161/JAHA.120.017970. View

19.

Zeng N, Huang Y, Yan Y, Hu Z, Zhang Z, Feng J . Diverging targets mediate the pathological roleof miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosis. Mol Ther Nucleic Acids. 2021; 26:1035-1050. PMC: 8571541. DOI: 10.1016/j.omtn.2021.10.013. View

20.

Li J, Salvador A, Li G, Valkov N, Ziegler O, Yeri A . Mir-30d Regulates Cardiac Remodeling by Intracellular and Paracrine Signaling. Circ Res. 2020; 128(1):e1-e23. PMC: 7790887. DOI: 10.1161/CIRCRESAHA.120.317244. View